Treatment of One Case with Cryoglobulinaemia Secondary to Connective Tissue Disease by Small Doses of Rituximab

Wang, X; Ning, Ya‐Xian; Wang, L; Zhang, J; Wang, Y; Shen, Hongfang

doi:10.7727/wimj.2014.384

Cited by 1 publication

(3 citation statements)

References 7 publications

(10 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…In the clinical prevention and treatment of UC, SLBZP can regulate immune function, decrease pro-inflammatory factors, increase anti-inflammatory factors, and regulate oxidative stress and the balance of gut microbiota ( Ma et al, 2019 ). Additionally, SLBZP can reduce the MMP-2 and MMP-9 levels and ameliorate intestinal mucosal permeability ( Wang, 2016 ). SLBZP, in combination with chemical drugs (such as mesalazine and sulfasalazine) and prescriptions (such as Tong Xie Yao Fang and Sishen pills), is generally prescribed in the current clinical practice.…”

Section: Clinical Research Of Slbzp In Treatment Of Ucmentioning

confidence: 99%

“…Meanwhile, SLBZP (granule/powder, oral 6 g each dose, 3 times a day) and mesalazine (oral 1 g, 3–4 times a day) combination exert immunomodulatory effect by changing the serum IgA and IgM levels as well as the ratio of Th17, Treg, CD4 + T, and CD8 + T cells ( Qian and Zhang, 2019 ; Tian et al, 2019 ). In addition, SLBZP (powder, oral 6 g each dose, 3 times a day) and mesalazine (oral 1 g, 3–4 times a day) in combination could decrease the serum MMP-2 and MMP-9 levels, ameliorate intestinal mucosa permeability, and improve the symptoms of UC patients ( Wang, 2016 ).…”

Section: Clinical Research Of Slbzp In Treatment Of Ucmentioning

confidence: 99%

“…MMP-2 and MMP-9 are the major gelatinases among MMPs, which can degrade collagen type IV to prevent cell infiltration and inflammatory proliferation. A clinical study indicated that SLBZP (1 dose per day, decocted in water, twice daily) could improve the symptoms of UC patients, and the mechanism may involve a decrease in the expression of MMP-2 and MMP-9 ( Wang, 2016 ).…”

Section: Studies Assessing the Mechanism Of Slbzp In The Treatment Of Ucmentioning

confidence: 99%

See 2 more Smart Citations

Traditional Chinese medicine prescription Shenling BaiZhu powder to treat ulcerative colitis: Clinical evidence and potential mechanisms

2022

View full text Add to dashboard Cite

Ulcerative colitis (UC), characterized by syndromes including abdominal pain, bloody stool, diarrhea, weight loss, and repeated relapse, is a non-specific inflammatory intestinal disease. In recent years, with the changing dietary habits in China, the incidence of UC has shown an upward trend. UC belongs to the category of recorded as “diarrhea,” “chronic dysentery,” and “hematochezia” in traditional Chinese medicine (TCM), and Shenling BaiZhu powder (SLBZP) is one of the most effective and commonly used prescriptions. In this review, we aim to systematically summarize the clinical application and pharmacological mechanism of SLBZP in the treatment of UC to provide a theoretical basis for its clinical use and experimental evaluation of SLBZP. Our results showed that both SLBZP and SLBZP in combination with chemical drugs, have a significant therapeutic effect against UC with few adverse reactions. Furthermore, combined therapy was better than western medicine. Further, pathophysiological studies indicated that SLBZP has anti-inflammatory, immunomodulatory, antioxidant effects, regulation relative cell signal transduction and regulation of gut microbiota. Although evidence suggests superior therapeutic efficacy of SLBZP for treating UC and the relative mechanism has been studied extensively, various shortcomings limit the existing research on the topic. There is a lack of UC animal models, especially UC with TCM syndromes, with no uniform standard and certain differences between the animal model and clinical syndrome. The dosage, dosage form, and therapeutic time of SLBZP are inconsistent and lack pharmacological verification, and clinical trial data are not detailed or sufficiently rigorous. In addition, SLSZP is composed of multiple Chinese drugs that contain massive numbers of ingredients and which or several components contribute to therapeutic effects. How they work synergistically together remains unknown. Therefore, on the one hand, large sample prospective cohort studies to clarify the clinical efficacy and safety of SLBZP in the treatment of UC are needed. In contrast, researchers should strengthen the study of the molecular biological mechanism of active ingredients and its synergistic actions, clarifying the mechanism of SLBZP in treating UC by multi-component, multi-target, and multi-pathway.

show abstract

Section: Clinical Research Of Slbzp In Treatment Of Ucmentioning

confidence: 99%

Section: Clinical Research Of Slbzp In Treatment Of Ucmentioning

confidence: 99%

Section: Studies Assessing the Mechanism Of Slbzp In The Treatment Of Ucmentioning

confidence: 99%

See 1 more Smart Citation

Traditional Chinese medicine prescription Shenling BaiZhu powder to treat ulcerative colitis: Clinical evidence and potential mechanisms

2022

View full text Add to dashboard Cite

show abstract

Treatment of One Case with Cryoglobulinaemia Secondary to Connective Tissue Disease by Small Doses of Rituximab

Abstract: Low-dose rituximab therapy for cryoglobulinaemia secondary to connective tissue diseases was safe and effective, and can be used as a treatment option in this condition.

Cited by 1 publication

References 7 publications

Traditional Chinese medicine prescription Shenling BaiZhu powder to treat ulcerative colitis: Clinical evidence and potential mechanisms

Traditional Chinese medicine prescription Shenling BaiZhu powder to treat ulcerative colitis: Clinical evidence and potential mechanisms

Contact Info

Product

Resources

About